ProShare Advisors
ADAP

ProShare Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

ProShare Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,466
Closed -$10.5K – 1955
2023
Q3 		$10.5K Buy
+13,466
New +$11.3K ﹤0.01% 1804
2023
Q2 		– Sell
-10,077
Closed -$11K – 1850
2023
Q1 		$11K Sell
10,077
-1,884
-16% -$2.92K ﹤0.01% 1763
2022
Q4 		$17.5K Sell
11,961
-124
-1% -$201 ﹤0.01% 1811
2022
Q3 		$13K Buy
12,085
+1,361
+13% +$2.5K ﹤0.01% 1730
2022
Q2 		$18K Sell
10,724
-3,479
-24% -$5.98K ﹤0.01% 1773
2022
Q1 		$29K Sell
14,203
-5,112
-26% -$13.8K ﹤0.01% 2150
2021
Q4 		$72K Sell
19,315
-9,958
-34% -$45.3K ﹤0.01% 2239
2021
Q3 		$151K Buy
29,273
+4,753
+19% +$21.3K ﹤0.01% 1845
2021
Q2 		$104K Buy
24,520
+5,680
+30% +$27.6K ﹤0.01% 2287
2021
Q1 		$100K Sell
18,840
-2,165
-10% -$12.4K ﹤0.01% 2166
2020
Q4 		$113K Buy
+21,005
New +$114K ﹤0.01% 1973
2019
Q4 		– Sell
-22,483
Closed -$34K – 1791
2019
Q3 		$34K Sell
22,483
-1,380
-6% -$3.23K ﹤0.01% 1621
2019
Q2 		$96K Sell
23,863
-3,405
-12% -$13.9K ﹤0.01% 1536
2019
Q1 		$117K Buy
27,268
+1,324
+5% +$6.17K ﹤0.01% 1555
2018
Q4 		$149K Sell
25,944
-1,146
-4% -$8.46K ﹤0.01% 1427
2018
Q3 		$367K Sell
27,090
-516
-2% -$5.41K ﹤0.01% 1257
2018
Q2 		$328K Sell
27,606
-2,399
-8% -$29.9K ﹤0.01% 1332
2018
Q1 		$337K Sell
30,005
-1,479
-5% -$12.9K ﹤0.01% 1262
2017
Q4 		$210K Buy
+31,484
New +$243K ﹤0.01% 1617

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

ProShare Advisors's ADAP Position: Q4 2023 in Review

ProShare Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q4 2023, closing a stake of 13,466 shares — an estimated $10.5K sold.

ProShare Advisors first reported a position in ADAP in Q4 2017 and held it in 19 quarters. The position peaked at $367K in Q3 2018. 79 funds tracked by Wall St. Rank hold ADAP as of Q4 2023.

  • ProShare Advisors reported no remaining Adaptimmune Therapeutics position as of Q4 2023 after selling out during the quarter.
  • ProShare Advisors sold 13,466 Adaptimmune Therapeutics shares in Q4 2023, an estimated $10.5K.
  • ProShare Advisors first reported a position in Adaptimmune Therapeutics in Q4 2017 and held it in 19 quarters.
  • ProShare Advisors's Adaptimmune Therapeutics position peaked at $367K in Q3 2018.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2023.

Based on ProShare Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.